Free Trial

Wall Street Zen Upgrades IN8bio (NASDAQ:INAB) to "Sell"

IN8bio logo with Medical background

Wall Street Zen upgraded shares of IN8bio (NASDAQ:INAB - Free Report) to a sell rating in a research report released on Saturday.

Separately, HC Wainwright decreased their price target on shares of IN8bio from $240.00 to $180.00 and set a "buy" rating on the stock in a research report on Friday, March 14th.

Get Our Latest Stock Report on IN8bio

IN8bio Stock Performance

IN8bio stock traded down $0.20 during midday trading on Friday, reaching $2.88. 286,740 shares of the company traded hands, compared to its average volume of 91,801. The firm has a market capitalization of $8.71 million, a price-to-earnings ratio of -3.84 and a beta of 0.18. The business has a 50 day moving average of $4.52 and a two-hundred day moving average of $6.85. IN8bio has a 12 month low of $2.82 and a 12 month high of $52.20. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84.

IN8bio (NASDAQ:INAB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($2.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.80) by ($0.30). As a group, research analysts predict that IN8bio will post -0.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC raised its position in IN8bio by 296.7% in the fourth quarter. Jane Street Group LLC now owns 115,919 shares of the company's stock worth $30,000 after acquiring an additional 86,696 shares during the period. Geode Capital Management LLC raised its position in shares of IN8bio by 56.5% during the 4th quarter. Geode Capital Management LLC now owns 515,193 shares of the company's stock valued at $133,000 after purchasing an additional 185,919 shares during the period. Sigma Planning Corp raised its position in shares of IN8bio by 22.3% during the 4th quarter. Sigma Planning Corp now owns 1,041,380 shares of the company's stock valued at $268,000 after purchasing an additional 190,100 shares during the period. AIGH Capital Management LLC raised its position in shares of IN8bio by 269.7% during the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company's stock valued at $1,593,000 after purchasing an additional 4,517,227 shares during the period. Finally, Alyeska Investment Group L.P. raised its position in shares of IN8bio by 1,064.5% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company's stock valued at $1,302,000 after purchasing an additional 4,628,482 shares during the period. 92.05% of the stock is currently owned by institutional investors.

About IN8bio

(Get Free Report)

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.

See Also

Should You Invest $1,000 in IN8bio Right Now?

Before you consider IN8bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IN8bio wasn't on the list.

While IN8bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines